HealthStream Inc. (NASDAQ:HSTM) earnings were flat in the first quarter compared to the same period a year ago. Earnings were $1.9 million, or 7 cents per share, on revenue of $38.4 million. HealthStream, Inc. (NASDAQ:HSTM) shares after opening at $24.29 moved to $24.88 on last trade day and at the end of the day closed at $22.91. Company price to sales ratio in past twelve months was calculated as 4.75 and price to cash ratio as 5.81. HealthStream, Inc. (NASDAQ:HSTM) showed a negative weekly performance of -4.86%.
ChinaNet Online Holdings, Inc. (NASDAQ:CNET) announced that on April 16, 2014, it received a letter from the Listing Qualifications Department of the NASDAQ Stock Market LLC (“NASDAQ”) advising the Company that, due to its inability to file with the Securities and Exchange Commission its annual report on Form 10-K for the fiscal year ended December 31, 2013 on a timely basis, the Company no longer complies with NASDAQ Listing Rule 5250(c)(1) for continued listing, and that the Company has 60 calendar days (or until June 16, 2014) to submit a plan explaining how it expects to regain compliance. Chinanet Online Holdings Inc. (NASDAQ:CNET) shares fell -5.51% in last trading session and ended the day on $1.20. CNET return on equity ratio is recorded as 6.90% and its return on assets is 5.30%. Chinanet Online Holdings Inc. (NASDAQ:CNET) yearly performance is 57.89%.
UBIC, Inc. (NASDAQ:UBIC), a leading provider of international litigation support and big-data analysis services, announced it will host another of its Signature Seminar Series in New York City, Friday, April 25. Ubic Inc. (ADR) (NASDAQ:UBIC) shares moved down -10.09% in last trading session and was closed at $8.64, while trading in range of $8.62 – $9.59. Ubic Inc. (ADR) (NASDAQ:UBIC) year to date (YTD) performance is 62.41%.
CollabRx, Inc. (NASDAQ:CLRX) and Affymetrix, Inc. (NASDAQ: AFFX) said they have announced on 17 April an agreement to optimize the use of CollabRx´s Genetic Variant Annotation Service in connection with Affymetrix´ OncoScan FFPE Assay Kit and CytoScan Cytogenetics Suite for analysis of gene copy number variation in cancer research. CollabRx Inc. (NASDAQ:CLRX) weekly performance is 2.00%. On last trading day company shares ended up $3.06. CollabRx Inc. (NASDAQ:CLRX) distance from 50-day simple moving average (SMA50) is -6.74%. Analysts mean target price for the company is $10.00.